Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Oral mucositis (inflammation of the lining of the mouth) is a very common adverse effect when
chemotherapy and radiation therapy are used to treat cancer. Mucositis occurs in about 40% of
patients receiving standard dose chemotherapy, 80% of patients receiving radiation therapy of
the head and neck, and up to 100% of patients undergoing a bone marrow transplant. Because
the pain from mucositis can be so bad it can cause the inability to eat or drink, inability
to talk, gagging and drooling. Many times mucositis can affect cancer treatment because
patients may have to be given a lower dose of a drug or stop treatment completely. There are
not many treatments today that can help relieve the severe pain caused from mucositis. This
research study will help researchers determine if using an oral mouthwash called Ketamine
will help lessen mucositis pain.
Ketamine is approved by the Food and Drug Administration (FDA) for use with general
anesthesia, sedation and for severe pain. WVU Hospital is now using Ketamine mouthwash as a
standard treatment option for mucositis pain.
During this study patients will be assessed to determine the level of pain caused by their
mucositis. This will occur before the first dose, one hour after the first dose, and then
daily until they are no longer on the study. Patients will use the mouthwash by swishing and
spitting (20mg/5ml) four times each day, and also every four hours as needed. Patients will
use the mouthwash on this study until their mucositis gets better or until the mucositis gets
worse (or if the pain does not get better after three days of treatment).